ClinicalTrials.gg
CompletedNCT00536263Updated Apr 7, 2017Results posted

PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)

A Phase 3 interventional study of pegylated interferon alpha-2b and pegylated interferon alpha-2b in Hepatitis B, Chronic, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-04-07.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
671
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing peginterferon alfa-2b in Hepatitis B, Chronic — 5 open to participants now, 5 under way, none of them phase 3. peginterferon alfa-2b · Hepatitis B, Chronic.

Enrollment
2nd of 15
671 · median 254
Started
2007
the only one that year
Phase 3
5 of 15
none open now
Registered
1st of 15
by date
Lead sponsor
3 of 15
Merck Sharp & Dohme LLC

Among the 15 studies testing peginterferon alfa-2b in Hepatitis B, Chronic, this one is the 2nd largest by enrollment, is the only one that started in 2007, is one of 5 in phase 3, and was the 1st registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

5 of the 15 studies testing peginterferon alfa-2b in Hepatitis B, Chronic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About peginterferon alfa-2b

peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing peginterferon alfa-2b in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy and safety of two dosages of PegIntron for treating hepatitis B e antigen (HBeAg) positive chronic hepatitis B compared with the approved dosage, which is PegIntron 1.0 microgram (mcg)/kg given once a week for 24 weeks. This study compares dosages of (1) 1.5 mcg/kg once a week for 24 weeks and (2) 1.5 mcg/kg once a week for 48 weeks with the approved dosage. All subjects are followed for 24 weeks after their treatment ends.

03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults with chronic :

    • Serum hepatitis B surface antigen positive for at least 6 months
    • Serum hepatitis B e antigen positive
    • Serum negative for hepatitis B surface and e antibodies
    • Plasma hepatitis B virus deoxyribonucleic acid (DNA) level greater than 20,000 IU/mL
    • (ALT) 2- to 10-times the
  • Compensated liver disease with certain minimum hematological and serum biochemical criteria

Exclusion criteria

Exclusion Criteria:

  • Significant hepatic disease from an etiology other than virus
  • Antiviral treatment for hepatitis within previous 6 months
  • History of severe psychiatric disease, especially depression
  • Unstable or significant cardiovascular disease
  • Prolonged exposure to known hepatotoxins such as alcohol or drugs
  • Any condition that could interfere with the subject participating in and completing the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
671 participants (actual)

Study arms

  • Active comparator
    PEG 1.0 mcg/kg weekly (QW) * 24 weeks

    PegIntron 1.0 mcg/kg weekly (QW) \* 24 weeks + 24 weeks follow-up

    Drug: pegylated interferon alpha-2b

  • Experimental
    PEG 1.5 mcg/kg QW * 24 wks

    PegIntron 1.5 mcg/kg QW \* 24 wks + 24 wks follow-up

    Drug: pegylated interferon alpha-2b

  • Experimental
    PEG 1.5 mcg/kg QW * 48 wks

    PegIntron 1.5 mcg/kg QW \* 48 wks + 24 wks follow-up

    Drug: pegylated interferon alpha-2b

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Hepatitis B Envelope Antigen (HBe or HBeAg) Loss

    HBeAg Loss was tested by Abbott Microparticle Enzyme Immunoassay (MEIA)

    Time frame: 24 weeks after end of treatment (EOT)

Secondary outcomes

  1. Number of Participants With HBeAg Loss

    HBeAg Loss was tested by assay of Abbott MEIA

    Time frame: Up to Treatment Week 48

  2. HBe Seroconversion

    HBe seroconversion was defined as HBeAg Loss and Anti-HBeAg Positive. These were tested by assay of Abbott MEIA.

    Time frame: End of treatment (EOT) and 24 weeks after EOT

  3. Number of Participants With Hepatitis B Virus - Deoxyriboncleic Acid (HBV-DNA) <20,000 IU/mL

    HBV-DNA was tested by assay of Roche Cobas Taqman (the test lowest limit is 6 IU/mL)

    Time frame: End of treatment (EOT) and 24 weeks after EOT

  4. Number of Participants With HBV-DNA < 200 IU/mL

    HBV-DNA was tested by assay of Roche Cobas Taqman (the test lowest limit is 6 IU/mL)

    Time frame: End of treatment (EOT) and 24 weeks after EOT

  5. Number of Participants With HBV-DNA Undetectable

    Undetectable HBV-DNA was defined as having a level \<6 IU/mL by polymerase chain reaction (PCR).

    Time frame: End of treatment (EOT) and 24 weeks after EOT

  6. Number of Participants With Biochemical Response

    Biochemical response was defined as alanine aminotransferase (ALT) normalization.

    Time frame: End of treatment (EOT) and 24 weeks after EOT

  7. Number of Participants With Combined Response

    Combined response was defined as HBV DNA \<20,000 IU/mL and HBe seroconversion and alanine aminotransferase (ALT) normalization

    Time frame: End of treatment (EOT) and 24 weeks after EOT

  8. Hepatitis B Surface Antigen (HBsAg) Loss

    HBsAg Loss was tested by assay of Abbott MEIA

    Time frame: End of treatment (EOT) and 24 weeks after EOT

  9. Hepatitis B Surface Antigen (HBs) Seroconversion

    HBs seroconversion was defined as having HBsAg Loss and Anti-HBs Positive

    Time frame: End of treatment (EOT) and 24 weeks after EOT

  10. Change From Baseline in Liver Biopsy Score

    Method for biopsy scoring was Knodell Scoring System (Histology Activity Index-HAI Score System): Score I (periportal +/- bridging necrosis): 0 (none) to 10 (multilobular necrosis). Score II (Intralobular degeneration and focal necrosis): 0 (none) to 4 (Marked \[involvement of \>2/3 of lobules or nodules\]). Score III (portal inflammation): 0 (none) to 4 (Marked \[dense packing of inflammatory cells in \>2/3 of portal tracts\]). Score IV (fibrosis): 0 (none) to 4 (cirrhosis).

    Time frame: Baseline to 24 weeks after end of treatment

07

Results

Posted Dec 21, 2010

Participant flow

Participant flow — Overall Study
MilestonePEG 1.0 mcg/kg Weekly (QW) * 24 WeeksPEG 1.5 mcg/kg QW * 24 WeeksPEG 1.5 mcg/kg QW * 48 Weeks
Started225221225
Completed214207204
Not completed111421
Withdrew: Adverse event557
Withdrew: Lost to follow-up344
Withdrew: Subject withdrew - not treatment related205
Withdrew: Subject withdrew - treatment related032
Withdrew: Noncompliance with protocol001
Withdrew: Did not meet protocol eligibility122

Outcome measures

PrimaryNumber of Participants With Hepatitis B Envelope Antigen (HBe or HBeAg) Loss

HBeAg Loss was tested by Abbott Microparticle Enzyme Immunoassay (MEIA)

Time frame:
24 weeks after end of treatment (EOT)
Reported as:
Number · Participants
Number of Participants With Hepatitis B Envelope Antigen (HBe or HBeAg) Loss
ParticipantsPEG 1.0 mcg/kg Weekly (QW) * 24 WeeksPEG 1.5 mcg/kg QW * 24 WeeksPEG 1.5 mcg/kg QW * 48 Weeks
Number of Participants With Hepatitis B Envelope Antigen (HBe or HBeAg) Loss394070
Statistical analysis
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 24 Weeks · Cochran-Mantel-Haenszel · p = 0.860 (P-values are unadjusted; Hochberg's adjustment for multiple comparisons was used to maintain the overall 0.05 significance level in test of superiority using the Cochran-Mantel-Haenszel test.) · Pairwise rate difference: 0.008 · 95% CI -0.063 to 0.079Stratified by genotype
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Cochran-Mantel-Haenszel · p = <0.001 (P-values are unadjusted; Hochberg's adjustment for multiple comparisons was used to maintain the overall 0.05 significance level in test of superiority using the Cochran-Mantel-Haenszel test.) · Pairwise rate difference: 0.139 · 95% CI 0.061 to 0.217Stratified by genotype
  • PEG 1.5 mcg/kg QW * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Pairwise rate difference: -0.132 · 90% CI -0.198 to -0.065
SecondaryNumber of Participants With HBeAg Loss

HBeAg Loss was tested by assay of Abbott MEIA

Time frame:
Up to Treatment Week 48
Reported as:
Number · Participants
Number of Participants With HBeAg Loss
ParticipantsPEG 1.0 mcg/kg Weekly (QW) * 24 WeeksPEG 1.5 mcg/kg QW * 24 WeeksPEG 1.5 mcg/kg QW * 48 Weeks
Number of Participants With HBeAg Loss312843
Statistical analysis
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 24 Weeks · Cochran-Mantel-Haenszel · p = 0.700 · Pairwise rate difference: -0.011 · 95% CI -0.074 to 0.052Stratified by genotype
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Cochran-Mantel-Haenszel · p = 0.125 · Pairwise rate difference: 0.054 · 95% CI -0.014 to 0.123Stratified by genotype
  • PEG 1.5 mcg/kg QW * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Pairwise rate difference: -0.065 · 90% CI -0.122 to -0.008
SecondaryHBe Seroconversion

HBe seroconversion was defined as HBeAg Loss and Anti-HBeAg Positive. These were tested by assay of Abbott MEIA.

Time frame:
End of treatment (EOT) and 24 weeks after EOT
Reported as:
Number · Participants
HBe Seroconversion
ParticipantsPEG 1.0 mcg/kg Weekly (QW) * 24 WeeksPEG 1.5 mcg/kg QW * 24 WeeksPEG 1.5 mcg/kg QW * 48 Weeks
EOT312740
24 weeks after EOT383667
Statistical analysis
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 24 Weeks · Cochran-Mantel-Haenszel · p = 0.598 · Pairwise rate difference: -0.016 · 95% CI -0.078 to 0.047Stratified by genotype
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Cochran-Mantel-Haenszel · p = 0.24 · Pairwise rate difference: 0.041 · 95% CI -0.027 to 0.108Stratified by genotype
  • PEG 1.5 mcg/kg QW * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Pairwise rate difference: -0.056 · 90% CI -0.112 to -0.001
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 24 Weeks · Cochran-Mantel-Haenszel · p = 0.830 · Pairwise rate difference: -0.006 · 95% CI -0.075 to 0.063Stratified by genotype
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Cochran-Mantel-Haenszel · p = 0.001 · Pairwise rate difference: 0.130 · 95% CI 0.053 to 0.208Stratified by genotype
  • PEG 1.5 mcg/kg QW * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Pairwise rate difference: -0.136 · 90% CI -0.201 to -0.071
SecondaryNumber of Participants With Hepatitis B Virus - Deoxyriboncleic Acid (HBV-DNA) <20,000 IU/mL

HBV-DNA was tested by assay of Roche Cobas Taqman (the test lowest limit is 6 IU/mL)

Time frame:
End of treatment (EOT) and 24 weeks after EOT
Reported as:
Number · Participants
Number of Participants With Hepatitis B Virus - Deoxyriboncleic Acid (HBV-DNA) <20,000 IU/mL
ParticipantsPEG 1.0 mcg/kg Weekly (QW) * 24 WeeksPEG 1.5 mcg/kg QW * 24 WeeksPEG 1.5 mcg/kg QW * 48 Weeks
EOT466176
24 weeks after EOT444775
Statistical analysis
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 24 Weeks · Cochran-Mantel-Haenszel · p = 0.076 · Pairwise rate difference: 0.072 · 95% CI -0.007 to 0.151Stratified by genotype
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Cochran-Mantel-Haenszel · p = 0.001 · Pairwise rate difference: 0.135 · 95% CI 0.053 to 0.216Stratified by genotype
  • PEG 1.5 mcg/kg QW * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Pairwise rate difference: -0.063 · 90% CI -0.135 to 0.009
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 24 Weeks · Cochran-Mantel-Haenszel · p = 0.662 · Pairwise rate difference: 0.017 · 95% CI -0.058 to 0.092Stratified by genotype
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Cochran-Mantel-Haenszel · p = <0.001 · Pairwise rate difference: 0.139 · 95% CI 0.059 to 0.220Stratified by genotype
  • PEG 1.5 mcg/kg QW * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Pairwise rate difference: -0.122 · 90% CI -0.191 to -0.053
SecondaryNumber of Participants With HBV-DNA < 200 IU/mL

HBV-DNA was tested by assay of Roche Cobas Taqman (the test lowest limit is 6 IU/mL)

Time frame:
End of treatment (EOT) and 24 weeks after EOT
Reported as:
Number · Participants
Number of Participants With HBV-DNA < 200 IU/mL
ParticipantsPEG 1.0 mcg/kg Weekly (QW) * 24 WeeksPEG 1.5 mcg/kg QW * 24 WeeksPEG 1.5 mcg/kg QW * 48 Weeks
EOT101421
24 weeks after EOT121222
Statistical analysis
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 24 Weeks · Cochran-Mantel-Haenszel · p = 0.373 · Pairwise rate difference: 0.019 · 95% CI -0.023 to 0.061Stratified by genotype
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Cochran-Mantel-Haenszel · p = 0.040 · Pairwise rate difference: 0.049 · 95% CI 0.003 to 0.096Stratified by genotype
  • PEG 1.5 mcg/kg QW * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Pairwise rate difference: -0.030 · 90% CI -0.072 to 0.011
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 24 Weeks · Cochran-Mantel-Haenszel · p = 0.969 · Pairwise rate difference: 0.001 · 95% CI -0.041 to 0.043Stratified by genotype
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Cochran-Mantel-Haenszel · p = 0.074 · Pairwise rate difference: 0.045 · 95% CI -0.004 to 0.094Stratified by genotype
  • PEG 1.5 mcg/kg QW * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Pairwise rate difference: -0.044 · 90% CI -0.085 to -0.003
SecondaryNumber of Participants With HBV-DNA Undetectable

Undetectable HBV-DNA was defined as having a level \<6 IU/mL by polymerase chain reaction (PCR).

Time frame:
End of treatment (EOT) and 24 weeks after EOT
Reported as:
Number · Participants
Number of Participants With HBV-DNA Undetectable
ParticipantsPEG 1.0 mcg/kg Weekly (QW) * 24 WeeksPEG 1.5 mcg/kg QW * 24 WeeksPEG 1.5 mcg/kg QW * 48 Weeks
EOT438
24 weeks after EOT438
Statistical analysis
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 24 Weeks · Cochran-Mantel-Haenszel · p = 0.724 · Pairwise rate difference: -0.004 · 95% CI -0.027 to 0.019Stratified by genotype
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Cochran-Mantel-Haenszel · p = 0.243 · Pairwise rate difference: 0.018 · 95% CI -0.012 to 0.048Stratified by genotype
  • PEG 1.5 mcg/kg QW * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Pairwise rate difference: -0.022 · 90% CI -0.046 to 0.002
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 24 Weeks · Cochran-Mantel-Haenszel · p = 0.724 · Pairwise rate difference: -0.004 · 95% CI -0.027 to 0.019Stratified by genotype
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Cochran-Mantel-Haenszel · p = 0.232 · Pairwise rate difference: 0.018 · 95% CI -0.012 to 0.048Stratified by genotype
  • PEG 1.5 mcg/kg QW * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Pairwise rate difference: -0.022 · 90% CI -0.046 to 0.002
SecondaryNumber of Participants With Biochemical Response

Biochemical response was defined as alanine aminotransferase (ALT) normalization.

Time frame:
End of treatment (EOT) and 24 weeks after EOT
Reported as:
Number · Participants
Number of Participants With Biochemical Response
ParticipantsPEG 1.0 mcg/kg Weekly (QW) * 24 WeeksPEG 1.5 mcg/kg QW * 24 WeeksPEG 1.5 mcg/kg QW * 48 Weeks
EOT7586103
24 weeks after EOT6380103
Statistical analysis
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 24 Weeks · Cochran-Mantel-Haenszel · p = 0.219 · Pairwise rate difference: 0.056 · 95% CI -0.033 to 0.145Stratified by genotype
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Cochran-Mantel-Haenszel · p = 0.006 · Pairwise rate difference: 0.126 · 95% CI 0.037 to 0.216Stratified by genotype
  • PEG 1.5 mcg/kg QW * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Pairwise rate difference: -0.071 · 90% CI -0.148 to 0.006
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 24 Weeks · Cochran-Mantel-Haenszel · p = 0.067 · Pairwise rate difference: 0.082 · 95% CI -0.004 to 0.168Stratified by genotype
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Cochran-Mantel-Haenszel · p = <0.001 · Pairwise rate difference: 0.180 · 95% CI 0.092 to 0.268Stratified by genotype
  • PEG 1.5 mcg/kg QW * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Pairwise rate difference: -0.098 · 90% CI -0.174 to -0.021
SecondaryNumber of Participants With Combined Response

Combined response was defined as HBV DNA \<20,000 IU/mL and HBe seroconversion and alanine aminotransferase (ALT) normalization

Time frame:
End of treatment (EOT) and 24 weeks after EOT
Reported as:
Number · Participants
Number of Participants With Combined Response
ParticipantsPEG 1.0 mcg/kg Weekly (QW) * 24 WeeksPEG 1.5 mcg/kg QW * 24 WeeksPEG 1.5 mcg/kg QW * 48 Weeks
EOT111123
24 weeks after EOT182345
Statistical analysis
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 24 Weeks · Cochran-Mantel-Haenszel · p = 0.995 · Pairwise rate difference: 0.001 · 95% CI -0.039 to 0.041Stratified by genotype
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Cochran-Mantel-Haenszel · p = 0.031 · Pairwise rate difference: 0.054 · 95% CI 0.005 to 0.103Stratified by genotype
  • PEG 1.5 mcg/kg QW * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Pairwise rate difference: -0.053 · 90% CI -0.094 to -0.012
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 24 Weeks · Cochran-Mantel-Haenszel · p = 0.389 · Pairwise rate difference: 0.024 · 95% CI -0.030 to 0.078Stratified by genotype
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Cochran-Mantel-Haenszel · p = <0.001 · Pairwise rate difference: 0.121 · 95% CI 0.058 to 0.184Stratified by genotype
  • PEG 1.5 mcg/kg QW * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Pairwise rate difference: -0.097 · 90% CI -0.152 to -0.041
SecondaryHepatitis B Surface Antigen (HBsAg) Loss

HBsAg Loss was tested by assay of Abbott MEIA

Time frame:
End of treatment (EOT) and 24 weeks after EOT
Reported as:
Number · Participants
Hepatitis B Surface Antigen (HBsAg) Loss
ParticipantsPEG 1.0 mcg/kg Weekly (QW) * 24 WeeksPEG 1.5 mcg/kg QW * 24 WeeksPEG 1.5 mcg/kg QW * 48 Weeks
EOT114
24 weeks after EOT114
Statistical analysis
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 24 Weeks · Cochran-Mantel-Haenszel · p = 0.991 · Pairwise rate difference: 0.000 · 95% CI -0.012 to 0.012Stratified by genotype
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Cochran-Mantel-Haenszel · p = 0.181 · Pairwise rate difference: 0.013 · 95% CI -0.006 to 0.033Stratified by genotype
  • PEG 1.5 mcg/kg QW * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Pairwise rate difference: -0.013 · 90% CI -0.030 to 0.003
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 24 Weeks · Cochran-Mantel-Haenszel · p = 0.971 · Pairwise rate difference: 0.000 · 95% CI -0.012 to 0.012Stratified by genotype
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Cochran-Mantel-Haenszel · p = 0.179 · Pairwise rate difference: 0.013 · 95% CI -0.006 to 0.033Stratified by genotype
  • PEG 1.5 mcg/kg QW * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Pairwise rate difference: -0.013 · 90% CI -0.030 to 0.003
SecondaryHepatitis B Surface Antigen (HBs) Seroconversion

HBs seroconversion was defined as having HBsAg Loss and Anti-HBs Positive

Time frame:
End of treatment (EOT) and 24 weeks after EOT
Reported as:
Number · Participants
Hepatitis B Surface Antigen (HBs) Seroconversion
ParticipantsPEG 1.0 mcg/kg Weekly (QW) * 24 WeeksPEG 1.5 mcg/kg QW * 24 WeeksPEG 1.5 mcg/kg QW * 48 Weeks
EOT001
24 weeks after EOT002
Statistical analysis
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 24 Weeks · Cochran-Mantel-Haenszel · p = 0.991Stratified by genotype Due to zero responses in the 2 arms, pairwise rate difference \& corresponding 95% confidence interval were not applicable.
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Cochran-Mantel-Haenszel · p = 0.322 · Pairwise rate difference: 0.004 · 95% CI -0.004 to 0.013Stratified by genotype
  • PEG 1.5 mcg/kg QW * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Pairwise rate difference: -0.004 · 90% CI -0.012 to 0.003
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 24 Weeks · Cochran-Mantel-Haenszel · p = 0.991Stratified by genotype Due to zero responses in the 2 arms, pairwise rate difference \& corresponding 95% confidence interval were not applicable.
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Cochran-Mantel-Haenszel · p = 0.157 · Pairwise rate difference: 0.009 · 95% CI -0.003 to 0.021Stratified by genotype
  • PEG 1.5 mcg/kg QW * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Pairwise rate difference: -0.009 · 90% CI -0.019 to 0.001
SecondaryChange From Baseline in Liver Biopsy Score

Method for biopsy scoring was Knodell Scoring System (Histology Activity Index-HAI Score System): Score I (periportal +/- bridging necrosis): 0 (none) to 10 (multilobular necrosis). Score II (Intralobular degeneration and focal necrosis): 0 (none) to 4 (Marked \[involvement of \>2/3 of lobules or nodules\]). Score III (portal inflammation): 0 (none) to 4 (Marked \[dense packing of inflammatory cells in \>2/3 of portal tracts\]). Score IV (fibrosis): 0 (none) to 4 (cirrhosis).

Time frame:
Baseline to 24 weeks after end of treatment
Reported as:
Mean · Units on a scale
Change From Baseline in Liver Biopsy Score
Units on a scalePEG 1.0 mcg/kg Weekly (QW) * 24 WeeksPEG 1.5 mcg/kg QW * 24 WeeksPEG 1.5 mcg/kg QW * 48 Weeks
Baseline8.0 ± 3.068.4 ± 2.928.2 ± 3.33
Change from Baseline-1.1 ± 3.57-1.7 ± 3.66-1.6 ± 3.96
Statistical analysis
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks · t-test, 2 sided · p = 0.014comparison of post-treatment versus baseline values
  • PEG 1.5 mcg/kg QW * 24 Weeks · t-test, 2 sided · p = <0.001comparison of post-treatment versus baseline values
  • PEG 1.5 mcg/kg QW * 48 Weeks · t-test, 2 sided · p = 0.010comparison of post-treatment versus baseline values
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 24 Weeks · ANCOVA · p = 0.631 · Pairwise rate difference: -0.2 · 95% CI -1.2 to 0.8Treatment group and genotype were the fixed effects and baseline was the covariate.
  • PEG 1.0 mcg/kg Weekly (QW) * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · ANCOVA · p = 0.617 · Pairwise rate difference: -0.3 · 95% CI -1.4 to 0.8Treatment group and genotype were the fixed effects and baseline was the covariate.
  • PEG 1.5 mcg/kg QW * 24 Weeks vs PEG 1.5 mcg/kg QW * 48 Weeks · Pairwise rate difference: 0.0 · 95% CI -1.1 to 1.1

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PEG 1.0 mcg/kg QW x24 Weeks—10/225 (4.4%)173/225 (76.9%)
PEG 1.5 mcg/kg QW x24 Weeks—11/221 (5%)169/221 (76.5%)
PEG 1.5 mcg/kg QW x48 Weeks—15/224 (6.7%)182/224 (81.3%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventPEG 1.0 mcg/kg QW x24 WeeksPEG 1.5 mcg/kg QW x24 WeeksPEG 1.5 mcg/kg QW x48 Weeks
ALANINE AMINOTRANSFERASE INCREASEDInvestigations1/2254/2212/224
ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations0/2254/2210/224
HEPATITISHepatobiliary disorders4/2250/2211/224
FATIGUEGeneral disorders1/2253/2210/224
DECREASED APPETITEMetabolism and nutrition disorders1/2253/2210/224
HEPATITIS BInfections and infestations1/2252/2213/224
DEPRESSIONPsychiatric disorders0/2252/2210/224
GASTROOESOPHAGEAL REFLUX DISEASEGastrointestinal disorders0/2251/2210/224
NAUSEAGastrointestinal disorders0/2251/2211/224
HEPATIC FUNCTION ABNORMALHepatobiliary disorders1/2251/2210/224
Most frequent other events
Most frequent other events
EventPEG 1.0 mcg/kg QW x24 WeeksPEG 1.5 mcg/kg QW x24 WeeksPEG 1.5 mcg/kg QW x48 Weeks
PYREXIAGeneral disorders156/225158/221168/224
MYALGIAMusculoskeletal and connective tissue disorders54/22570/22177/224
HEADACHENervous system disorders47/22566/22159/224
FATIGUEGeneral disorders35/22529/22142/224
ALOPECIASkin and subcutaneous tissue disorders15/22519/22128/224
ASTHENIAGeneral disorders12/22525/22115/224
DIZZINESSNervous system disorders18/22521/22122/224
ARTHRALGIAMusculoskeletal and connective tissue disorders18/22514/22112/224
DECREASED APPETITEMetabolism and nutrition disorders8/22516/22117/224
WEIGHT DECREASEDInvestigations5/2253/22116/224

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PEG 1.0 mcg/kg QW * 24 WeeksPEG 1.5 mcg/kg QW * 24 WeeksPEG 1.5 mcg/kg QW * 48 WeeksTotal
Mean28.2 ± 7.227.5 ± 7.128.4 ± 7.628.0 ± 7.3
Sex: Female, Male
Sex: Female, Male(Participants)PEG 1.0 mcg/kg QW * 24 WeeksPEG 1.5 mcg/kg QW * 24 WeeksPEG 1.5 mcg/kg QW * 48 WeeksTotal
Female545755166
Male171164169504
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Cheng J, Wang Y, Hou J, Luo D, Xie Q, Ning Q, Ren H, Ding H, Sheng J, Wei L, Chen S, Fan X, Huang W, Pan C, Gao Z, Zhang J, Zhou B, Chen G, Wan M, Tang H, Wang G, Yang Y, Mohamed R, Guan R, Lee TH, Chang WH, Zhenfei H, Ye Z, Xu D. Peginterferon alfa-2b in the treatment of Chinese patients with HBeAg-positive chronic hepatitis B: a randomized trial. J Clin Virol. 2014 Dec;61(4):509-16. doi: 10.1016/j.jcv.2014.08.008. Epub 2014 Aug 18. PubMed 25200354 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2007
First posted
Sep 27, 2007
Start
Sep 2007
Primary completionActual
Nov 2009
CompletionActual
Nov 2009
Results first posted
Dec 21, 2010
Last update
Apr 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00536263
Responsible party
Sponsor
First posted
Sep 27, 2007
Start date
Sep 2007
Primary completion
Nov 2009
Completion
Nov 2009
Results posted
Dec 21, 2010
Last update
Apr 7, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2b

Start the discussion